{"id":"dose-mfolfirinox","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Peripheral neuropathy"},{"rate":"20-30","effect":"Anemia"},{"rate":"10-20","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"mFOLFIRINOX combines 5-fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin. 5-FU and leucovorin inhibit thymidylate synthase to disrupt DNA synthesis; irinotecan inhibits topoisomerase I to prevent DNA unwinding; and oxaliplatin forms DNA cross-links. Together, these agents create multiple mechanisms of cytotoxic stress on rapidly dividing cancer cells.","oneSentence":"mFOLFIRINOX is a combination chemotherapy regimen that uses multiple cytotoxic agents to damage cancer cell DNA and inhibit cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:53.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer (first-line treatment)"}]},"trialDetails":[{"nctId":"NCT07490301","phase":"PHASE2, PHASE3","title":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-06-03","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, PDAC","enrollment":900},{"nctId":"NCT06818812","phase":"PHASE1","title":"A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-03-27","conditions":"Solid Tumors","enrollment":30},{"nctId":"NCT06179160","phase":"PHASE1","title":"A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2024-01-04","conditions":"Solid Tumors","enrollment":710},{"nctId":"NCT07469956","phase":"PHASE2","title":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-31","conditions":"Pancreatic Cancer Resectable","enrollment":30},{"nctId":"NCT05968326","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-10-18","conditions":"Adenocarcinoma, Pancreatic Ductal","enrollment":260},{"nctId":"NCT05174169","phase":"PHASE2, PHASE3","title":"Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-10","conditions":"Stage III Colon Cancer","enrollment":1912},{"nctId":"NCT06048484","phase":"PHASE2","title":"Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Gulam Manji","startDate":"2024-05-10","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT06648434","phase":"PHASE1","title":"MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-05-15","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Cancer of the Pancreas","enrollment":51},{"nctId":"NCT07166601","phase":"PHASE1","title":"M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2025-10-10","conditions":"Advanced Solid Tumor","enrollment":77},{"nctId":"NCT06384560","phase":"PHASE1, PHASE2","title":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2024-09-23","conditions":"Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma","enrollment":66},{"nctId":"NCT05365581","phase":"PHASE1","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-06-07","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":398},{"nctId":"NCT06360354","phase":"PHASE1","title":"A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-05-29","conditions":"Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers","enrollment":350},{"nctId":"NCT05412082","phase":"PHASE1","title":"SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2022-10-05","conditions":"Locally Advanced Rectal Cancer","enrollment":25},{"nctId":"NCT03977233","phase":"PHASE2","title":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-06-12","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult","enrollment":45},{"nctId":"NCT07255404","phase":"PHASE2","title":"A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-12-04","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":105},{"nctId":"NCT03443492","phase":"PHASE2","title":"SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-03-26","conditions":"Locally Advanced or Metastatic Pancreatic Cancer","enrollment":130},{"nctId":"NCT07280377","phase":"PHASE1, PHASE2","title":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","status":"RECRUITING","sponsor":"Oncolytics Biotech","startDate":"2021-10-27","conditions":"Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic","enrollment":122},{"nctId":"NCT06922591","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","status":"RECRUITING","sponsor":"Tango Therapeutics, Inc.","startDate":"2025-05-31","conditions":"PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC","enrollment":183},{"nctId":"NCT06396091","phase":"PHASE1","title":"A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-09-24","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":12},{"nctId":"NCT05458219","phase":"PHASE1","title":"A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-10-26","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors","enrollment":470},{"nctId":"NCT04325425","phase":"PHASE2","title":"Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-09-01","conditions":"Neuroendocrine Carcinoma","enrollment":218},{"nctId":"NCT05209074","phase":"PHASE1","title":"Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2022-09-08","conditions":"Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer","enrollment":16},{"nctId":"NCT07155629","phase":"PHASE3","title":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2025-09-01","conditions":"Pancreatic Cancer Resectable","enrollment":381},{"nctId":"NCT07114861","phase":"PHASE1, PHASE2","title":"The KN510713 Study in Combination With mFOLFIRINOX","status":"NOT_YET_RECRUITING","sponsor":"New Cancer Cure-Bio Co.,Ltd.","startDate":"2025-10-22","conditions":"Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":30},{"nctId":"NCT05132504","phase":"PHASE2","title":"Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2022-08-31","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT04292743","phase":"PHASE1","title":"Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2020-12-02","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":19},{"nctId":"NCT04251715","phase":"PHASE2","title":"mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-04-28","conditions":"Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","enrollment":5},{"nctId":"NCT04793932","phase":"PHASE3","title":"Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Associazione Italiana per lo Studio del Pancreas","startDate":"2020-11-03","conditions":"Pancreas Ductal Adenocarcinoma","enrollment":261},{"nctId":"NCT04229004","phase":"PHASE3","title":"A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Pancreatic Cancer Action Network","startDate":"2020-01-31","conditions":"Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":502},{"nctId":"NCT06892054","phase":"PHASE2","title":"Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2025-06-30","conditions":"Pancreatic Adenocarcinoma","enrollment":15},{"nctId":"NCT06278454","phase":"PHASE1","title":"Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)","status":"RECRUITING","sponsor":"Chengdu New Radiomedicine Technology Co. LTD.","startDate":"2024-01-09","conditions":"Unresectable Pancreatic Cancer","enrollment":58},{"nctId":"NCT06888648","phase":"PHASE1, PHASE2","title":"Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2025-04-01","conditions":"Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable","enrollment":30},{"nctId":"NCT06757244","phase":"PHASE2","title":"DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer","status":"RECRUITING","sponsor":"Hopital Foch","startDate":"2025-02-18","conditions":"Pancreas Neoplasms","enrollment":35},{"nctId":"NCT04627246","phase":"PHASE1","title":"Personalized Vaccine with SOC Chemo Followed by Nivo in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2020-09-11","conditions":"Pancreatic Adenocarcinoma","enrollment":14},{"nctId":"NCT04911816","phase":"PHASE1, PHASE2","title":"Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"West Virginia University","startDate":"2021-07-16","conditions":"Adenocarcinoma of the Pancreas","enrollment":40},{"nctId":"NCT05257993","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Onconic Therapeutics Inc.","startDate":"2022-03-30","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT02672917","phase":"PHASE1","title":"Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies","status":"TERMINATED","sponsor":"BioNTech Research & Development, Inc.","startDate":"2016-01","conditions":"Pancreatic Cancer","enrollment":118},{"nctId":"NCT03699319","phase":"PHASE1, PHASE2","title":"CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"David Bajor, MD","startDate":"2018-12-07","conditions":"Pancreatic Cancer","enrollment":49},{"nctId":"NCT01821612","phase":"EARLY_PHASE1","title":"Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2013-05-29","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":23},{"nctId":"NCT06572813","phase":"PHASE1, PHASE2","title":"Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2024-11-15","conditions":"Pancreas Cancer","enrollment":63},{"nctId":"NCT06761027","phase":"PHASE1, PHASE2","title":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fujian Provincial Hospital","startDate":"2024-12-23","conditions":"Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":29},{"nctId":"NCT02581215","phase":"PHASE2","title":"Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Walid Shaib, MD","startDate":"2016-09-11","conditions":"Pancreatic Cancer","enrollment":84},{"nctId":"NCT05314998","phase":"PHASE3","title":"Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature","status":"NOT_YET_RECRUITING","sponsor":"John Neoptolemos","startDate":"2025-01-15","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":394},{"nctId":"NCT06389760","phase":"PHASE2","title":"Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-10-18","conditions":"Pancreatic Cancer","enrollment":57},{"nctId":"NCT03885284","phase":"PHASE1","title":"Study of Proton Therapy in Adjuvant Pancreatic Cancer","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2019-07-15","conditions":"Resected Pancreatic Adenocarcinoma","enrollment":9},{"nctId":"NCT05462496","phase":"PHASE2","title":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-03-16","conditions":"Pancreatic Cancer","enrollment":25},{"nctId":"NCT06391892","phase":"PHASE3","title":"Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery","status":"RECRUITING","sponsor":"Elisabethinen Hospital","startDate":"2024-01-11","conditions":"Pancreatic Cancer, Circulating Tumor Cell, Predictive Cancer Model","enrollment":100},{"nctId":"NCT05912075","phase":"PHASE1","title":"Preoperative Radiotherapy And ASTX660 in Rectum Cancer","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2023-12-19","conditions":"Locally-advanced Rectal Cancer","enrollment":78},{"nctId":"NCT06156267","phase":"EARLY_PHASE1","title":"Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-01","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT01835041","phase":"PHASE1","title":"CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-04","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":21},{"nctId":"NCT05083247","phase":"PHASE2","title":"Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Erasme University Hospital","startDate":"2023-03-24","conditions":"Pancreatic Neoplasm, Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":256},{"nctId":"NCT03099265","phase":"PHASE2","title":"Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma","status":"TERMINATED","sponsor":"Yale University","startDate":"2017-06-26","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT05580887","phase":"","title":"Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients","status":"UNKNOWN","sponsor":"Moscow Clinical Scientific Center","startDate":"2022-05-12","conditions":"Breast Cancer, Pancreas Cancer","enrollment":35},{"nctId":"NCT01560949","phase":"PHASE2","title":"Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-14","conditions":"Pancreatic Cancer","enrollment":34},{"nctId":"NCT02405585","phase":"PHASE2","title":"Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2015-04","conditions":"Pancreatic Cancer, Pancreatic Carcinoma Non-resectable","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dose -mFOLFIRINOX","genericName":"Dose -mFOLFIRINOX","companyName":"Pancreatic Cancer Action Network","companyId":"pancreatic-cancer-action-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"mFOLFIRINOX is a combination chemotherapy regimen that uses multiple cytotoxic agents to damage cancer cell DNA and inhibit cell division. Used for Metastatic pancreatic cancer (first-line treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}